Wednesday, June 21, 2017 9:03:54 PM
Company will be debt free after DSM & Co transaction is completed!
You seemingly haven't analyzed the DSM & Co offerings.
Post tranche-a _and_ b, company may have received about $280.90M fully diluted, which brings equity from $(212.19M) to $68.71M.
This includes the cash warrants naturally.
This assumes a floor price of $6.30 per share, at least for tranche-a and the second tranche also targets the same price as stated in the proxy material.
The anti-dilutive warrants haven't been triggered, allowing a sub $6.30 share price.
Found this sensible analysis of the tranche-a deal RS adjusted:
.. and the corresponding fundamentals, see below.
Well, that is a heck of dilution, however, they are paying a good price for it, 132% premium as of today!
In the end it is clear that they takeover the company. Old shareholder far above $9 may not recover this year, but the transaction surely fixes company's balance sheet and removes all BK risks completely.
At the current price, this seems to be a very bullish case.
Yes, the whole transaction still needs to settle, voting is on 7/7 for AMRS for conversion and tranche-b. DSM also needs to sign for the tranche-b. Also company then needs to produce the positive cash flow in 2018, but w/ DSM this shall be no issue.
A short term bounce is the least possible right now, knowing company just became listing compliant again and had a double bottom.
You seemingly haven't analyzed the DSM & Co offerings.
Post tranche-a _and_ b, company may have received about $280.90M fully diluted, which brings equity from $(212.19M) to $68.71M.
This includes the cash warrants naturally.
This assumes a floor price of $6.30 per share, at least for tranche-a and the second tranche also targets the same price as stated in the proxy material.
The anti-dilutive warrants haven't been triggered, allowing a sub $6.30 share price.
Found this sensible analysis of the tranche-a deal RS adjusted:
.. and the corresponding fundamentals, see below.
Well, that is a heck of dilution, however, they are paying a good price for it, 132% premium as of today!
In the end it is clear that they takeover the company. Old shareholder far above $9 may not recover this year, but the transaction surely fixes company's balance sheet and removes all BK risks completely.
At the current price, this seems to be a very bullish case.
Yes, the whole transaction still needs to settle, voting is on 7/7 for AMRS for conversion and tranche-b. DSM also needs to sign for the tranche-b. Also company then needs to produce the positive cash flow in 2018, but w/ DSM this shall be no issue.
A short term bounce is the least possible right now, knowing company just became listing compliant again and had a double bottom.
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
